Future cancer research priorities in the USA: a Lancet Oncology Commission.
Future cancer research priorities in the USA: a Lancet Oncology Commission.
复制标题
DOI：
10.1016/s1470-2045(17)30698-8
复制
发表时间：
2017-11
期刊：
影响因子：
--
通讯作者：
Yung A
中科院分区：
文献类型：
--
作者：
Jaffee EM;Dang CV;Agus DB;Alexander BM;Anderson KC;Ashworth A;Barker AD;Bastani R;Bhatia S;Bluestone JA;Brawley O;Butte AJ;Coit DG;Davidson NE;Davis M;DePinho RA;Diasio RB;Draetta G;Frazier AL;Futreal A;Gambhir SS;Ganz PA;Garraway L;Gerson S;Gupta S;Heath J;Hoffman RI;Hudis C;Hughes-Halbert C;Ibrahim R;Jadvar H;Kavanagh B;Kittles R;Le QT;Lippman SM;Mankoff D;Mardis ER;Mayer DK;McMasters K;Meropol NJ;Mitchell B;Naredi P;Ornish D;Pawlik TM;Peppercorn J;Pomper MG;Raghavan D;Ritchie C;Schwarz SW;Sullivan R;Wahl R;Wolchok JD;Wong SL;Yung A
我们正处于一场技术革命之中，这场技术革命为人类生物学和癌症提供了新的见解。在这个大数据时代，我们正在积累大量信息，这些信息正在改变我们治疗和预防癌症的方式。美国《21 世纪治愈法案》中癌症登月计划的颁布恰逢知识进步的有利时刻，为癌症研究和精准医疗提供了近 20 亿美元的资金。 2016 年，蓝带小组 (BRP) 制定了一份建议路线图，旨在探索癌症诊断、预防和治疗方面的新进展。这些建议提供了如何加速将新科学发现转化为有效的癌症治疗和预防的高层次观点。美国国家癌症研究所已经在实施其中一些建议。作为 BRP 确定的优先领域的专家，我们支持这些建议以实施这一重要的科学路线图。在本委员会中，我们更详细地审查 BRP 建议，并将讨论范围扩大到其他优先领域，包括外科肿瘤学、放射肿瘤学、影像学、卫生系统和健康差异、监管和融资、人口科学和肿瘤政策。我们优先考虑美国的研究领域，我们相信这些领域将加速造福癌症患者的努力。最后，我们希望本报告中的建议能够促进新的国际合作，进一步加强全球在癌症控制方面的努力。
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.
影响因子：
3.1
作者：
Sigurdardottir, Katrin Ruth;Haugen, Dagny Faksavg;Bausewein, Claudia;Higginson, Irene J.;Harding, Richard;Rosland, Jan Henrik;Kaasa, Stein
通讯作者：
Kaasa, Stein